In this study, the authors found that despite tumor regression induced by treatment with carbozantinib, tumors residing in areas adjacent to newly remodeled bone remained viable, and they further identified that resistance was due to enhanced tumor cell viability mediated by integrin activation of focal adhesion kinase (FAK). Here, PTK2 is linked to neoplasm.